Jubilant Therapeutics Presents Early Clinical Data for JBI-802 in Blood Cancers

Jubilant Therapeutics has unveiled initial clinical data from its Phase 1/2 study of JBI-802, an oral dual LSD1/HDAC6 inhibitor, for patients with myeloproliferative neoplasms (MPNs). Presented at SOHO 2026, the findings offer early evidence supporting this dual inhibition as a distinct therapeutic strategy for blood cancers like essential thrombocythemia and polycythemia vera. This marks a preliminary step in developing new treatments for these conditions.